Piperacillin Inj Rx
Generic Name and Formulations:
Piperacillin sodium 2g, 3g, 4g; per vial; pwd for IM or IV inj after reconstitution; IV infusion after reconstitution and dilution; sodium content 42.5mg/g piperacillin sodium.
Various generic manufacturers
Indications for Piperacillin Inj:
Serious susceptible infections, including lower respiratory tract, intraabdominal, septicemia, skin and skin structure, bone and joint, UTIs, gynecological infections, and uncomplicated gonoccocal urethritis. Surgical prophylaxis in intraabdominal (GI and biliary) procedures, vaginal and abdominal hysterectomy, and cesarean section.
Give by IM inj into upper outer quadrant of buttock; or IV inj over 3–5 minutes; or IV infusion over 20–30 minutes. Max dose: 24g/day. IM inj: max 2g per injection site. May give 1g probenecid orally ½ hour prior to inj. Serious infections: 12–18g/day IV (200–300mg/kg/day) in divided doses every 4–6 hours. Complicated UTIs: 8–16g/day IV (125–200mg/kg/day) in divided doses every 6–8 hours. Uncomplicated UTIs and community-acquired pneumonia: 6–8g/day IM or IV (100–125mg/kg/day) in divided doses every 6–12 hours. Uncomplicated gonorrhea infections: 2g IM once as a single dose. All: treat for 7–10 days; gynecological infections: 3–10 days; Streptococcus pyogenes infections: at least 10 days. Acute infections: continue therapy 48–72 hours after patient becomes asymptomatic. Prophylaxis, renal impairment, or hemodialysis: see literature.
Beta-lactam allergy including cephalosporins.
Renal impairment. Salt-restricted. Monitor renal, hepatic, hematopoietic function in prolonged use. Discontinue if bleeding disorder occurs. Cystic fibrosis (increased fever/rash risk). Gonorrhea infections: do serologic test for syphilis at baseline and 3 months after therapy. Pregnancy (Cat.B). Nursing mothers.
Potentiated by probenecid. Antagonizes aminoglycosides. May potentiate non-depolarizing muscle relaxants (eg, vercuronium). Monitor methotrexate, heparin, anticoagulants. May cause false (+) with Clinitest, Benedict's or Fehling's soln, Coomb's test.
Inj site reactions, GI disturbances, rash (may be severe, eg, Stevens-Johnson syndrome), headache, dizziness, fatigue, seizures, renal impairment, anaphylaxis, blood dyscrasias, bleeding.
Formerly known under the brand name Pipracil.
Endocrinology Advisor Articles
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Concurrent Risk Factors and Microvascular Complications in Type 1 Diabetes
- Higher Risk for Meningioma Linked to GH Treatment, Radiotherapy During Childhood
- Early Treatment Intensification and Faster Glycemic Control in T2D
- Comparing Antidiabetic Drug Classes for Risk of Heart Failure
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- Ivacaftor Improves Insulin Secretion in Children With Cystic Fibrosis
- Genetic Testing Recommended for Familial Hypercholesterolemia
- Behavioral Weight Loss Interventions May Prevent Obesity
- Disaster Preparedness 101: Physician Resources for Patients
- Assessing the Environmental Impact of the Healthcare Industry